Metabolic syndrome increases the incidence of several cancers, including colorectal and endometrial cancers.
Research output on MetS and cancer has grown significantly, particularly from China and the US.
MetS is associated with poorer oncologic outcomes, including higher recurrence rates and reduced survival.
Targeted correction of MetS components can enhance treatment efficacy in cancer patients.
A systematic bibliometric approach is necessary to map knowledge gaps in MetS-cancer research.
Guideline-Based Recommendations
Diagnosis
MetS is diagnosed based on the presence of any three of five parameters: dysglycemia, elevated blood pressure, elevated triglycerides, reduced HDL cholesterol, and abdominal obesity.
Management
Focus on weight reduction and improved insulin sensitivity to enhance treatment efficacy in cancer patients.
Monitoring & Follow-up
Regular assessment of MetS components is essential for cancer patients to improve outcomes.
Risks
MetS promotes a pro-tumorigenic environment, facilitating tumor initiation and metastasis.
Patient & Prescribing Data
Patients with metabolic syndrome at risk for cancer
Addressing metabolic dysfunction may improve cancer prognosis and treatment tolerance.
Clinical Best Practices
Implement region-specific preventive strategies for MetS.
Encourage early detection of MetS in at-risk populations.
